Northwell’s AI Tool iNav Cuts Pancreatic Cancer Diagnosis Time by Half

Event summary

  • Northwell Health’s AI tool iNav reduced the time from imaging scan to biopsy from 12 days to 6 days for pancreatic cancer patients.
  • The study, published in The Oncologist, involved 71 patients and showed iNav accelerated treatment timelines by 21 days.
  • iNav analyzes over 10,000 MRI and CT scan reports weekly across Northwell’s 28-hospital network.
  • The tool won Northwell’s 2023 Innovation Challenge, securing $500,000 in seed funding.
  • iNav was named to TIME’s Best Inventions list in 2024.

The big picture

Northwell’s iNav represents a significant advancement in AI-driven cancer diagnostics, addressing a critical gap in early pancreatic cancer detection. The tool’s ability to reduce diagnosis and treatment timelines aligns with broader industry trends toward precision medicine and health equity. With increasing recognition and funding, iNav could become a benchmark for AI applications in oncology.

What we're watching

Scalability
Whether iNav can maintain its efficiency as it scales beyond Northwell’s network.
Regulatory Approval
The pace at which iNav secures broader regulatory approval for widespread clinical use.
Commercialization
How Northwell plans to monetize iNav, given its current in-house status.

Related topics

Technology